In addition, a high‐throughput cell‐based screening for licensing inhibitors also prioritized a small‐molecule inhibitor for replication licensing factor, RL5a, which can restrain the binding of ORC to DNA and compromise MCM2–7 loading onto origins, thereby successfully reducing the proliferation of cancer cells.51 This evidence concerns the gene MCM2 and cancer.